There are 2137 resources available
189P - The prognostic value of androgen receptor in triple negative breast cancer
Presenter: Dian Pratiwi
Session: E-Poster Display
Resources:
Abstract
190P - Impact of chemotherapy for early stage breast cancer on quality of life in older adults: Results from 2811 women enrolled in the Bridging the Age Gap study
Presenter: Nicolò Matteo Luca Battisti
Session: E-Poster Display
Resources:
Abstract
191P - Therapeutic drug monitoring of tamoxifen to improve adjuvant treatment of hormone sensitive breast cancer: The TOTAM study
Presenter: Louwrens Braal
Session: E-Poster Display
Resources:
Abstract
192P - The association between endocrine therapy use and osteoporotic fracture among post-menopausal women treated for early-stage breast cancer in Ontario, Canada
Presenter: Phillip Blanchette
Session: E-Poster Display
Resources:
Abstract
193P - Adjuvant capecitabine-containing chemotherapy is effective in both BRCA1-like and non-BRCA1-like early-stage TNBC patients
Presenter: Leonora de Boo
Session: E-Poster Display
Resources:
Abstract
194P - Neoadjuvant immunotherapy plus chemotherapy in early triple-negative breast cancer: A meta-analysis of randomized controlled trials
Presenter: Jessa Gilda Pandy
Session: E-Poster Display
Resources:
Abstract
195P - Neoadjuvant chemotherapy (NACT) use and response in US patients with early-stage triple-negative breast cancer in the National Cancer Database (NCDB)
Presenter: Mehr Kashyap
Session: E-Poster Display
Resources:
Abstract
196P - Neoadjuvant and adjuvant chemotherapy (NACT/ACT) treatment (tx) patterns in a real-world cohort of US pts with early triple-negative breast cancer (eTNBC)
Presenter: Leisha Emens
Session: E-Poster Display
Resources:
Abstract
197P - Comparative safety of Epirubicin and cyclophosphamide versus Docetaxel and cyclophosphamide in lymph node negative, HR-positive, HER2-negative breast cancer (ELEGANT): A randomized trial
Presenter: Deyue Liu
Session: E-Poster Display
Resources:
Abstract
198P - Patient & oncologist preferences for adjuvant CDK4/6i therapy in HR+/HER2- early breast cancer
Presenter: Kathleen Beusterien
Session: E-Poster Display
Resources:
Abstract